-
Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib
Zwierenga, F., Muntinghe-Wagenaar, M. B., Rozendal, P., de Langen, A. J., Hendriks, L. E. L., van den Heuvel, M., van der Leest, C., Hashemi, S. M. S., van der Leest, P., Hiltermann, T. J. N., Schuuring, E. & van der Wekken, A. J., Jul 2025, In: Targeted oncology. 20, 4, p. 663-677 15 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
van der Wel, J. W. T., Jebbink, M., van den Broek, D., Steinbusch, L. C., Theelen, W. S. M. E., Ruiter, G., Buikhuisen, W., Burgers, J. A., Baas, P., Vermeulen, M., van der Noort, V., Hashemi, S. M. S., Bosch, L. J. W., Monkhorst, K., Smit, E. F., Boelens, M. C. & de Langen, A. J., 1 Dec 2024, In: Lung Cancer. 198, 107972.Research output: Contribution to journal › Article* › Academic › peer-review
-
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol
Verkerk, K., van der Wel, T. J. W. T., Zeverijn, L. J., Geurts, B. S., Spiekman, I. A. C., de Wit, G. F., Roepman, P., Jansen, A. M. L., van der Noort, V., Smit, E. F., Hoeben, A., Hendriks, L. E. L., van den Heuvel, M. M., Piet, B., Herder, G. J. M., Hashemi, S. M. S., Gelderblom, H., Verheul, H. M. W., Voest, E. E. & de Langen, A. J., 1 Dec 2024, In: Clinical cancer research. 30, 23, p. 5323-5332Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
